Q&A: Legend Biotech CEO on whether Carvykti can meet expectations

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 15, 2024 at 11:43: AM
via With the multiple myeloma drug’s climb from fifth- to second-line therapy, Carvykti uptake is set to expand. Legend Biotech CEO Ying Huang discusses timing of a crucial supply bump.

article source
 

<



Similar threads

cafead
Legend Biotech CEO takes ‘close look at business’ amid geopolitical risk, M&amp;A rumor
Replies
0
Views
10
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
J&amp;J’s CAR-T partner Legend Biotech reportedly receives buyout offer
Replies
0
Views
90
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
J&amp;J partner Legend Biotech looks to raise $250M amid Carvykti rollout, global expansion
Replies
0
Views
81
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Biotech J&amp;J-backed CAR-T biotech Legend guns for $100M IPO but sees CRS death in early...
Replies
0
Views
119
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
J&amp;J, Legend&#039;s Carvykti shows CAR-T can extend lives in multiple myeloma
Replies
0
Views
25
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote